Semaglutide

The Semaglutide evidence base cited here is 8 sources — 5 clinical, 2 regulatory. Its strongest evidence is human — 5 clinical studies, most recently 2023 ("Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SEL…"). Regulatory status: FDA-approved (Ozempic/Wegovy).

Cross-trial comparison only — different trials, populations, and endpoints. Only tirzepatide-vs-semaglutide has been tested head-to-head (SURPASS-2), where tirzepatide won.

*Retatrutide's 28.7% is reported topline, pending peer-reviewed publication. See the tirzepatide and retatrutide research pages for the full breakdowns. All three are built on the same His-Aib-Glu-Gly-Thr-Phe… N-terminal incretin backbone — what differs is the receptor targets (GLP-1 → +GIP → +glucagon), the fatty-acid chain and half-life (~7 / ~5 / ~6 days), and peak efficacy.

• Semaglutide is a GLP-1 receptor agonist from Novo Nordisk — the drug that turned GLP-1 therapy into a household name. FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral diabetes).
• In the STEP 1 obesity trial it produced 14.9% mean weight loss at 68 weeks (vs 2.4% placebo), with about a third of participants losing ≥20%.
• The SELECT trial showed a 20% reduction in major cardiovascular events in overweight/obese adults without diabetes — proving the heart benefit is independent of blood-sugar effects.

Semaglutide is the GLP-1 receptor agonist that reset expectations for weight-loss medicine. It mimics the natural incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve glucose control — and once-weekly dosing made it practical at scale.

It started as a diabetes drug (Ozempic, 2017), then earned a dedicated obesity approval (Wegovy, 2021) after trials showed double-digit weight loss. It's the single-receptor benchmark that the dual-agonist tirzepatide and the triple-agonist retatrutide are measured against.

Semaglutide is a synthetic analog of human GLP-1 — an incretin hormone the gut releases after eating. Structural tweaks (an amino-acid substitution plus a fatty-acid chain that binds albumin) give it a ~7-day half-life, which is what allows once-weekly injection rather than the daily dosing older analogs like liraglutide require.

It also exists as an oral tablet (Rybelsus) — a real pharmaceutical feat for a ~4,114 Da peptide. A co-formulant (SNAC) briefly raises stomach pH to shield it from degradation and aid absorption, but oral bioavailability is only ~1%, which is why oral doses are in milligrams while the injection is in micrograms, and why Rybelsus must be taken on an empty stomach.

Structurally it is a 31-amino-acid analog: the fatty-acid chain is a C18 diacid attached through a γ-glutamate (γ-Glu) spacer, which is what drives the strong albumin binding behind the ~7-day half-life. After a subcutaneous dose, plasma levels peak at roughly 1 day and the compound is largely cleared within about 35 days.

Semaglutide uses a mandatory step-up schedule to limit GI side effects. Any step can be held longer if side effects persist, and escalation can stop once the target is reached.

No cycling needed — evidence supports continuous long-term use. But the STEP 1 extension (Wilding et al., 2022) found participants regained roughly two-thirds of lost weight within a year of stopping, so it's a chronic therapy.

• Weeks 1–4 (0.25 mg): appetite suppression often starts in week one; modest early loss; GI adjustment.
• Weeks 5–12 (0.5–1.0 mg): clear appetite reduction and steady loss; fasting glucose improves.
• Weeks 13–20 (1.7–2.4 mg): waist, blood pressure, and lipids improve; GI effects usually settle.
• Weeks 20–68: STEP 1 averaged 14.9% loss at 68 weeks on 2.4 mg, ~1/3 of participants hitting ≥20%; continued use sustains it, stopping leads to gradual regain.

GI effects dominate, especially during escalation, and are mostly self-limiting.

Tolerability tips from the trials: hold each titration step the full 4 weeks (escalating too fast is the #1 cause of dropout), eat smaller lower-fat meals, and stay hydrated.

Sometimes combined for body composition, but with real caveats. Research context, not protocol advice.

• Metformin — well established in diabetes, complementary mechanism, additive weight benefit.
• Testosterone / anabolics — used to preserve lean mass during cutting, but evidence is weak: semaglutide cuts skeletal muscle about as much as plain caloric restriction does.
• GH secretagogues (tesamorelin, ipamorelin) — experimental/off-label; both classes affect glucose, so caution.
• Tirzepatide — switching between them is common, but do NOT run both at once (overlapping mechanism, no added benefit, much higher side-effect risk).

• Ozempic/Wegovy pens: refrigerate at 2–8°C until first use; Ozempic then up to 56 days at room temp (≤30°C) or fridge; Wegovy (single-use) up to 28 days outside the fridge; protect from light, don't freeze.
• Research-grade lyophilized powder: reconstitute with bacteriostatic water down the vial wall, swirl (don't shake); refrigerate the solution at 2–8°C, use within ~28 days, protect from light, avoid freeze-thaw. Small volumes require insulin syringes for accurate dosing.

• Ozempic — approved 2017 for type 2 diabetes.
• Wegovy — approved 2021 for chronic weight management (and adolescents 12+ via STEP TEENS).
• Rybelsus — oral semaglutide for diabetes (7/14/21 mg).
• Oral Wegovy — 25 mg daily tablet approved December 2025 for chronic weight management; the first oral GLP-1 cleared for weight loss (supported by OASIS 4).
• Compounded semaglutide sits in a gray area allowed during shortages; the FDA has warned about quality and incorrect salt forms (semaglutide sodium vs base).

Research-grade semaglutide sold 'not for human consumption' is unregulated — purchase is generally legal, but human use happens outside any quality oversight.

Semaglutide is not on the WADA Prohibited List and isn't banned in most sports. It does raise fairness questions in weight-class sports, and some bodies are monitoring GLP-1 use. A practical risk for tested athletes: compounded or research-grade products can contain undisclosed substances that trigger a positive test — verify status with your governing body.

On the Huberman Lab podcast, Dr. Abud Bakri credited pharma for the engineering behind semaglutide: native GLP-1 (whose biology traces partly to Gila-monster-saliva research) is too short-acting, and the value was in extending its half-life into a usable drug. He noted that bodybuilders pioneered GLP-1 weight-loss use in the late 2010s before formal FDA weight-loss approval.

On staying on the drug, he leaned on set-point / settling-point theory — body weight is a daily brain calculation integrating many hormones, and a GLP-1 is a large 'don't eat' signal, so stopping often leads to regain. He worried less about lifelong use (cost and access permitting) than about the 'much shorter life of obesity,' while still asking his recurring 'free lunch?' question.

Expert clinical opinion; the framing is cautious optimism, not a recommendation, and semaglutide should be used under medical supervision.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.